One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLD MRI

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 52-59

  Schunck, Thérèse ^a   Mathis, Alexandre ^a   Erb, Gilles ^a   Namer, Izzie Jacques ^a   Hode, Yann ^a   Demazières, Agnès ^a   Luthringer, Rémy ^a  

^a FORENAP   (France)

Author keywords

anxiety; benzodiazepine; CCK 4; fMRI; lorazepam; panic attacks

Indexed keywords

LORAZEPAM; PLACEBO; TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; ATTENTION; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; HEART RATE; HUMAN; INSULA; MALE; PANIC; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATE TRAIT ANXIETY INVENTORY; VISUAL ANALOG SCALE;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; ATTENTION; CEREBRAL CORTEX; CROSS-OVER STUDIES; GYRUS CINGULI; HEART RATE; HUMANS; LORAZEPAM; MAGNETIC RESONANCE IMAGING; MALE; PANIC; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; TETRAGASTRIN; YOUNG ADULT;

EID: 78650619143     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110367449     Document Type: Article

References (22)

1. Arce E., Miller DA, Feinstein JS, Stein MB and Paulus MP (2006) Lorazepam dose-dependently decreases risk-taking related activation in limbic areas. Psychopharmacology 189: 105-116.
2. Bond A. and Lader M. (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
3. Bradwejn J., Koszycki D. and Shriqui C. (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48: 603-610.
4. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J. and Sedman A. (1995) Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38: 742-746.
5. Charney DS and Woods SW (1989) Benzodiazepine treatment of panic disorders: a comparison of alprazolam and lorazepam. J Clin Psychiatry 50: 418-423.
6. Cloninger CR (1987) A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44: 573-588.
7. De Montigny C. (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46: 511-517.
8. Genovese CR, Lazar NA and Nichols T. (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15: 870-878.
9. Hennel F. (1998) Image-based reduction of artifacts in multishot echo-planar imaging. J Magn Reson 134: 206-213.
10. Koszycki D., Zacharko RM, Le Medello JM and Bradwejn J. (1998) Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 8: 1-7.
11. Lecrubier Y., Sheehan DV, Weiller E., et al. (1997) The MINI International Neuropsychiatric Interview (MINI). a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12: 224-231. (Pubitemid 27298915)
12. Le Mellédo JM, Bradwejn J., Koszycki D., Bichet DG and Bellavance F. (1998) The role of the β-noradrenergic system in cholecystokinin- tetrapeptide-induced panic symptoms. Biol Psychiatry 44: 364-366.
13. Nikou C., Heitz F., Armspach JP, Namer IJ and Grucker D. (1998) Registration of MR/MR and MR/SPECT brain images by fast stochastic optimisation of robust voxel similarity measures. Neuroimage 8: 30-43.
14. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97-113.
15. Paulus MP, Feinstein JS, Castillo G., Simmons AN and Stein MB (2005) Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62: 282-288.
16. Schunck T., Erb G., Mathis A., et al. (2006) Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31: 1197-1208.
17. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T. and Bradwejn J. (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332-340.
18. Sperling R., Greve D., Dale A., et al. (2002) Functional MRI detection of pharmacologically-induced memory impairment. Proc Natl Acad Sci USA 99: 455-460.
19. Spielberger CD, Gorsuch RL, Lushene R., Vagg PR and Jacobs GA (1983) Manual for the State-trait Anxiety Inventory (Form Y). Palo Alto: Consulting Psychologists Press Inc.
20. Van Megen HJGM, Westenberg HGM, den Boer JA and Kahn RS (1996) Review: Cholecystokinin in anxiety. Eur Neuropsychopharmacol 6: 263-280.
21. Van Megen HJGM, Westenberg HGM, den Boer JA, Slaap B. and Scheepmakers A. (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 129: 357-364.
22. Zwanzger P., Eser D., Aicher S., et al. (2003) Effect of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal- axis activity: a placebo-controlled study. Neuropsychopharmacology 28: 979-984.